Quantcast
Last updated on April 16, 2014 at 13:28 EDT

Latest Roche Group Stories

2012-03-19 02:24:42

TUCSON, Ariz., March 19, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is now introducing a novel platform for special stains, built on its industry-leading VENTANA BenchMark technology. Answering customers' challenges with their current process, the new BenchMark Special Stains platform offers walk-away automation, baking through staining including deparaffinization, random batch access, connectivity to the VANTAGE workflow solution, and...

2012-03-01 06:00:00

TUCSON, Ariz., March 1, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA has approved the application of its INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) on the VENTANA BenchMark ULTRA automated slide staining platform for commercialization in the United States. Originally approved by the FDA in June 2011 for use with the BenchMark XT instrument, the HER2 Dual ISH assay is now approved for use on...

2012-02-27 06:00:00

TUCSON, Ariz., Feb. 27, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Ki-67 (30-9) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software. Ventana is currently the only company offering an FDA cleared Ki-67 image analysis algorithm for determining Ki-67 expression levels in breast cancer...

2012-01-17 06:00:00

TUCSON, Ariz., Jan. 17, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a strategic collaboration agreement with Bayer Pharma AG (Bayer) to develop a molecular companion diagnostic test intended to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC). Ventana's diagnostic immunohistochemistry platform aims to analyze the expression level of certain tumor...

2012-01-10 07:00:00

TUCSON, Jan. 10, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a collaboration agreement with Pfizer Inc. and license agreement with Cell Signaling Technology (CST) to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements. Ventana will develop the test which is intended to identify non-small cell lung cancer (NSCLC)...

2012-01-05 06:30:00

Collaboration is part of Aeterna Zentaris' personalized medicine approach for AEZS-108 as a treatment for multiple cancers QUÉBEC CITY, Jan. 5, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it entered into a collaboration agreement with Ventana Medical Systems, Inc., a member of the Roche Group, to develop a companion diagnostic for the immunohistochemical determination of luteinizing hormone-releasing...

2011-12-13 08:00:00

TUCSON, Ariz., Dec. 13, 2011 /PRNewswire/ -- Ventana Medical Systems Inc. (Ventana), a member of the Roche Group, and Advanced Cell Diagnostics Inc. (ACD), announced today they have entered a worldwide co-promotion agreement for the first commercially available, fully automated RNA in situ hybridization (ISH) assay system capable of robust detection and visualization of virtually any expressed gene in routine clinical specimens at single-molecule sensitivity. (Photo:...

2011-10-27 08:00:00

TUCSON, Ariz., Oct. 27, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today a first-of-its-kind integration of the VIRTUOSO digital pathology software and VANTAGE workflow management solution, bringing unprecedented workflow integration to the anatomic pathology lab. The VIRTUOSO -VANTAGE integration enables pathologists and lab managers to track the progress of a slide from preparation to digitization along with other critical slide...

2011-10-24 10:51:00

TUCSON, Ariz., Oct. 24, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm HER2 (4B5) for image analysis applications with associated VIRTUOSO software and iScan Coreo Au scanner. Ventana is now the only company with a complete workflow solution for determining HER2 (4B5) expression in breast cancer patients. The application assists the...

2011-10-04 12:00:00

TUCSON, Ariz., Oct. 4, 2011 /PRNewswire/ -- The VENTANA anti-Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody (H. pylori) is the first H. pylori antibody to receive 510(k) clearance from the Food and Drug Administration (FDA). Developed by Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, the VENTANA H. pylori antibody, when used in immunohistochemical (IHC) staining, aids in the detection of Helicobacter pylori, a bacterium linked to chronic gastritis,...